Benefits of lumican on human bone health: clinical evidence using bone marrow aspirates
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Lumican, a small leucine-rich proteoglycan, has shown osteoprotective effects by synchronously stimulating bone formation and suppressing bone resorption. To clarify the role of lumican in human bone metabolism, the association between lumican concentrations and osteoporosis-related phenotypes was evaluated using bone marrow (BM) samples directly reflecting local microenvironments. Methods: BM aspirates were obtained from 77 patients during hip surgery for either fragility hip fractures (HF) (n = 29) or osteoarthritis (n = 48) and centrifuged. Concentrations of lumican and biochemical bone markers in BM supernatants were measured using enzyme linked immunosorbent assays. Results: After considering confounders, lumican concentrations in BM supernatants were 16.9% lower in patients with HF than in controls, with each increase in the standard deviation of lumican concentration being associated with a 61% lower likelihood of HF. The odds ratios for HF decreased linearly with increasing lumican tertiles in BM, with the odds of having fragility HF markedly lower in participants in the highest than in the lowest lumican tertile. Higher lumican level correlated significantly with higher femur neck bone mineral density and higher bone-specific alkaline phosphatase levels, but not with tartrate-resistant acid phosphatase 5b concentrations, in BM supernatants. Conclusions: These data clinically validate previous in vitro and animal experiments showing the beneficial roles of lumican for bone homeostasis and suggest that lumican may contribute to a reduction in fracture risk in humans mainly through its stimulation of bone formation.
Abstract
Background/Aims: Lumican, a small leucine-rich proteoglycan, has shown osteoprotective effects by synchronously stimulating bone formation and suppressing bone resorption. To clarify the role of lumican in human bone metabolism, the association between lumican concentrations and osteoporosis-related phenotypes was evaluated using bone marrow (BM) samples directly reflecting local microenvironments. Methods: BM aspirates were obtained from 77 patients during hip surgery for either fragility hip fractures (HF) (n = 29) or osteoarthritis (n = 48) and centrifuged. Concentrations of lumican and biochemical bone markers in BM supernatants were measured using enzyme linked immunosorbent assays. Results: After considering confounders, lumican concentrations in BM supernatants were 16.9% lower in patients with HF than in controls, with each increase in the standard deviation of lumican concentration being associated with a 61% lower likelihood of HF. The odds ratios for HF decreased linearly with increasing lumican tertiles in BM, with the odds of having fragility HF markedly lower in participants in the highest than in the lowest lumican tertile. Higher lumican level correlated significantly with higher femur neck bone mineral density and higher bone-specific alkaline phosphatase levels, but not with tartrate-resistant acid phosphatase 5b concentrations, in BM supernatants. Conclusions: These data clinically validate previous in vitro and animal experiments showing the beneficial roles of lumican for bone homeostasis and suggest that lumican may contribute to a reduction in fracture risk in humans mainly through its stimulation of bone formation.
참고문헌 (19)
- 배그린, "Disability Weights for Osteoporosis and Osteoporotic Fractures in South Korea", 대한골대사학회지, 26(2), pp.83~88 (2019), 대한골대사학회
- 차용한, "Establishment of Fracture Liaison Service in Korea: Where Is It Stand and Where Is It Going?", 대한골대사학회지, 26(4), pp.207~211 (2019), 대한골대사학회
- 안승희, "Osteoporosis and Osteoporotic Fracture Fact Sheet in Korea", 대한골대사학회지, 27(4), pp.281~290 (2020), 대한골대사학회
- Jacques P. Brown, "Long-Term Treatment of Postmenopausal Osteoporosis", Endocrinology and Metabolism, 36(3), pp.544~552 (2021), 대한내분비학회[DOI]
- Kim BJ, "Coupling factors involved in preserving bone balance", Cell Mol Life Sci, 76, pp.1243~1253 (2019)
- 민용기, "Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis", Endocrinology and Metabolism, 30(1), pp.19~26 (2015), 대한내분비학회
- Reyes C, "Risks and benefits of bisphosphonate therapies", J Cell Biochem, 117, pp.20~28 (2016)
- 백기현, "Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study", Endocrinology and Metabolism, 36(1), pp.60~69 (2021), 대한내분비학회[DOI]
- Canalis E, "Mechanisms of anabolic therapies for osteoporosis", N Engl J Med, 357, pp.905~916 (2007)
- Blochberger TC, "cDNA to chick lumican(corneal keratan sulfate proteoglycan)reveals homology to the small interstitial proteoglycan gene family and expression in muscle and intestine", J Biol Chem, 267, pp.347~352 (1992)
- Nikitovic D, "Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells", FEBS J, 275, pp.350~361 (2008)
- D’Onofrio MF, "Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican", Biochem Biophys Res Commun, 365, pp.266~272 (2008)
- Lee JY, "Muscle-derived lumican stimulates bone formation via integrin α2β1 and the downstream ERK signal", Front Cell Dev Biol, 8, pp.565826~ (2020)
- Lee JY, "Lumican inhibits osteoclastogenesis and bone resorption by suppressing Akt activity", Int J Mol Sci, 22, pp.4717~ (2021)
- Drake MT, "Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women", J Clin Endocrinol Metab, 95, pp.5056~5062 (2010)
- Schaefer L, "Biological functions of the small leucine-rich proteoglycans : from genetics to signal transduction", J Biol Chem, 283, pp.21305~21309 (2008)
- Merline R, "The matricellular functions of small leucine-rich proteoglycans(SLRPs)", J Cell Commun Signal, 3, pp.323~335 (2009)
- Bi Y, "Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts", Bone, 38, pp.778~786 (2006)
- Nuka S, "Phenotypic characterization of epiphycan-deficient and epiphycan", biglycan double-deficient mice, 2010, pp.18, 88~96